Search Saint Luke's

Anthony Weatherspoon, 68, of Lee’s Summit, Missouri, remembers it like it was yesterday: The day he wasn’t feeling very well in 2024. “I didn’t know what was up,” Anthony says, with his wife, Peggy, at his side.

The use of prescription drugs for ADHD has significantly increased in the past few decades. James O'Keefe, MD studies the link between these medications and cardiovascular events.

The groundbreaking STEP-HFpEF study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named one of the top advances by the American Heart Association.

On the day after Andrew Widman returned home from Saint Luke’s Hospital of Kansas City with his new heart, his wife, Vicki, drove him to the DMV. There he ordered a personalized license plate that read simply “745.” It’s a number that’s particularly close to his heart.

BBC News talked to Dr. Mikhail Kosiborod about new findings on the cardiovascular effects of semaglutide.

Jim Mitchell faced a dilemma — miss rehearsal for a play he was producing during crunch time, or risk having a heart attack. Read his story.

A growing body of evidence correlates shorter running sessions to significant health benefits, especially those regarding longevity and mental health.

A team of cardiologists has used cardiac imaging technology to confirm that cardiovascular disease was a significant issue thousands of years ago.

Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.

Percutaneous coronary intervention is associated with significant short-term improvements in high-risk patients with complex coronary artery disease who are ineligible for coronary artery bypass grafting, according to a new analysis.